Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants

NCT02608853 · Completed

Last updated 2026-05-28

This clinical trial is studying the rate of cancer diagnoses in people with type 2 diabetes who are starting a medication called liraglutide, compared to a similar group in a previous study.

Status Completed The study has finished.

Type Observational

Participants 9,999 people

Who can join all sexes

Timeline Started 2015-01 · est. completion 2015-01

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02608853 ↗

Description as written by the study sponsor.

This study is conducted in the United States of America. The aim of this study is to estimate incidence rates of all malignant neoplasms, specific subgroups of malignant neoplasms, and acute pancreatitis among cohorts of antidiabetic drug users standardized to be representative of LEADER™ trial participants or liraglutide initiators within the Humedica Electronic Health Record (EHR) database.

Treatments tested

No treatment given Other

No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.

Main thing measured	Incidence of all malignant neoplasms
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02608853 ↗